209 related articles for article (PubMed ID: 30650179)
1. JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma.
Dolatabadi S; Jonasson E; Lindén M; Fereydouni B; Bäcksten K; Nilsson M; Martner A; Forootan A; Fagman H; Landberg G; Åman P; Ståhlberg A
Int J Cancer; 2019 Jul; 145(2):435-449. PubMed ID: 30650179
[TBL] [Abstract][Full Text] [Related]
2. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
3. FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.
Dolatabadi S; Jonasson E; Andersson L; Luna Santamaría M; Lindén M; Österlund T; Åman P; Ståhlberg A
Front Oncol; 2022; 12():816894. PubMed ID: 35186752
[TBL] [Abstract][Full Text] [Related]
4. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
5. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.
Safavi S; Järnum S; Vannas C; Udhane S; Jonasson E; Tomic TT; Grundevik P; Fagman H; Hansson M; Kalender Z; Jauhiainen A; Dolatabadi S; Stratford EW; Myklebost O; Eriksson M; Stenman G; Schneider-Stock R; Ståhlberg A; Åman P
Oncotarget; 2016 Jan; 7(1):433-45. PubMed ID: 26595521
[TBL] [Abstract][Full Text] [Related]
6. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma.
Tornin J; Martinez-Cruzado L; Santos L; Rodriguez A; Núñez LE; Oro P; Hermosilla MA; Allonca E; Fernández-García MT; Astudillo A; Suarez C; Morís F; Rodriguez R
Oncotarget; 2016 May; 7(21):30935-50. PubMed ID: 27105533
[TBL] [Abstract][Full Text] [Related]
8. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract][Full Text] [Related]
9. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
[TBL] [Abstract][Full Text] [Related]
11. Curcumin-Mediated Apoptotic Cell Death in Papillary Thyroid Cancer and Cancer Stem-Like Cells through Targeting of the JAK/STAT3 Signaling Pathway.
Khan AQ; Ahmed EI; Elareer N; Fathima H; Prabhu KS; Siveen KS; Kulinski M; Azizi F; Dermime S; Ahmad A; Steinhoff M; Uddin S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936675
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced secretion stimulates breast cancer stem cell regulatory signalling pathways.
Jacobsson H; Harrison H; Hughes É; Persson E; Rhost S; Fitzpatrick P; Gustafsson A; Andersson D; Gregersson P; Magnusson Y; Ståhlberg A; Landberg G
Mol Oncol; 2019 Aug; 13(8):1693-1705. PubMed ID: 31066211
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Invasion of Human Glioblastoma U87 Cell Line by Ruxolitinib: A Molecular Player of miR-17 and miR-20a Regulating JAK/STAT Pathway.
Delen E; Doganlar O; Doganlar ZB; Delen O
Turk Neurosurg; 2020; 30(2):182-189. PubMed ID: 31452174
[TBL] [Abstract][Full Text] [Related]
14. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
[TBL] [Abstract][Full Text] [Related]
15. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
[TBL] [Abstract][Full Text] [Related]
16. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
[TBL] [Abstract][Full Text] [Related]
17. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
18. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cells as a therapeutic target in 3D tumor models of human chondrosarcoma: An encouraging future for proline rich polypeptide‑1.
Granger CJ; Hoyt AK; Moran A; Becker B; Sedani A; Saigh S; Conway SA; Brown J; Galoian K
Mol Med Rep; 2020 Nov; 22(5):3747-3758. PubMed ID: 32901865
[TBL] [Abstract][Full Text] [Related]
20. MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells.
Liu L; Gaboriaud N; Vougogianopoulou K; Tian Y; Wu J; Wen W; Skaltsounis L; Jove R
Cancer Biol Ther; 2014 Feb; 15(2):178-84. PubMed ID: 24100507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]